Skip to main content
Teva Pharmaceutical Industries Ltd. logo

Teva Pharmaceutical Industries Ltd. — Investor Relations & Filings

Ticker · TEVA ISIN · US8816242098 LEI · 549300BAFGM4RC74ZJ94 TA Manufacturing
Open in API
Filings indexed 6,049 across all filing types
Latest filing 2026-04-30 Interim / Quarterly Rep…
Country IL Israel
Listing TA TEVA

About Teva Pharmaceutical Industries Ltd.

https://www.tevapharm.com/

Teva Pharmaceutical Industries Ltd. is a global biopharmaceutical company that develops, produces, and markets a broad portfolio of medicines. The company's business is centered on two main segments: generic medicines and innovative specialty treatments. As one of the world's largest manufacturers of generic drugs, Teva provides a wide range of affordable products across numerous therapeutic areas. Its specialty and biopharmaceutical research focuses on developing novel treatments, with a significant emphasis on central nervous system (CNS) disorders, including therapies for schizophrenia, tardive dyskinesia, and bipolar disorder. The company's portfolio also includes complex generics, biosimilars, and active pharmaceutical ingredients (APIs), while leveraging advanced technologies to enhance drug development and manufacturing.

Recent filings

Filing Released Lang Actions
Immediate Report
Interim / Quarterly Report Classification · 1% confidence The document is a Form 10-Q with unaudited consolidated financial statements, MD&A, risk factors, and other disclosures for the quarterly period ended March 31, 2026. It is clearly an interim/quarterly report, not merely an announcement. Therefore, it should be classified as an Interim / Quarterly Report (IR). Q1 2026
2026-04-30 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an Immediate Report under Israeli Securities Regulation 4, stating that the company has attached its Q1 2026 Form 10-Q (“דוחות כספיים מלאים לרבעון הראשון 2026”) as a PDF and provides a link for an accessible version. The text itself does not contain financial statements but merely announces the report’s publication. Therefore, this is a Report Publication Announcement.
2026-04-30 English
8K: Q1 2026 RESULTS
Earnings Release Classification · 1% confidence The document is a Form 8-K current report primarily containing Teva’s press release of first quarter 2026 financial results (Item 2.02), with key revenue figures, EPS, outlook, and highlights. This matches an Earnings Release (initial announcement of quarterly financial results). Q1 2026
2026-04-29 English
8K: Q1 2026 RESULTS
Report Publication Announcement Classification · 1% confidence The document is an Israeli ‘Immediate Report’ on Q1 2026 results filed via MAGNA, referencing an attached PDF press release (Q126_8K_Press_Release_PR_tables_isa.pdf) and directing readers to Teva’s website for the full release. The body contains no financial tables itself, merely an announcement that the report is attached. Under the “menu vs meal” rule, this is a report publication announcement rather than the report itself.
2026-04-29 English
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
Regulatory Filings
2026-04-29 English
Immediate Report
Proxy Solicitation & Information Statement Classification · 1% confidence The document is an SEC Schedule 14A “Proxy Statement” with definitive additional materials for Teva’s 2026 annual shareholders’ meeting, detailing proposals to be voted on, voting instructions, and notice of availability of proxy materials. This corresponds to proxy solicitation and information statements rather than reporting financial results or announcing an upcoming report. Therefore, it is classified as a Proxy Solicitation & Information Statement (PSI).
2026-04-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.